Trevi Therapeutics, Inc. (TRVI)
$12.29-4.95%Close
SELLCRISIS · day 21
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.7B
- Beta
- 0.98
- P/E (TTM)
- -36.38
- Short % float
- 12.33%
- Days to cover
- 8.3
- SI change
- +21.3%
- 1W
- -6.75%
- 1M
- -22.66%
- vs SPY 1W
- -6.61%
- vs SPY 1M
- -25.16%
Industry peers
FMP comparable companies · ranked by market cap
- ACADSELLAcadia Pharmaceuticals Inc.$3.2BCRISISQ 17$18.62-4.07%
- VCRESELLVicore Pharma Holding AB$2.5BQ -63$8.95-3.03%
- LQDASELLLiquidia Corporation$2.4BCRISISQ 12$26.81-3.11%
- RAPPSELLRapport Therapeutics, Inc. Common Stock$1.4BCRISISQ 24$28.99-3.85%
- TBPHBUYTheravance Biopharma Inc$884MBULLQ -1$17.03+0.00%
- LXRXSELLLexicon Pharmaceuticals, Inc.$715MCRISISQ 5$1.61-2.42%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on TRVI?
- LOPJLB’s latest quantitative signal on Trevi Therapeutics, Inc. (TRVI) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is TRVI in?
- Trevi Therapeutics, Inc. (TRVI) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Trevi Therapeutics, Inc. (TRVI) do?
- Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experien…